Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator

Ryosuke Matsuda ¹, Ryosuke Maeoka ², Takayuki Morimoto ²

⁰Department of Neurosurgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. rmatsuda@naramed-u.ac.jp.

Journal of Neuro-Oncology +

|

April 24, 2024

View abstract on PubMed

Summary

The systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) can predict overall survival in primary central nervous system lymphoma (PCNSL) patients. Lower SIRI and SII values are associated with longer survival, indicating their prognostic value.

Area Of Science

Oncology
Immunology
Hematology

Background

The systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) are emerging biomarkers derived from routine blood counts.
These indices reflect the balance between inflammatory and immune cells, implicated in cancer progression.
Their prognostic role in primary central nervous system lymphoma (PCNSL) requires further investigation.

Purpose Of The Study

To evaluate the prognostic significance of SIRI and SII in patients diagnosed with PCNSL.
To determine if these inflammatory markers can predict overall survival (OS) in PCNSL patients.

Main Methods

Retrospective analysis of 47 PCNSL patients with available blood test data and follow-up.
Exclusion of patients on steroids or with elevated C-reactive protein at the time of blood draw.
Receiver operating characteristic (ROC) curve analysis to determine optimal cutoff values for SIRI and SII for predicting OS.

Main Results

A low SIRI ( < 1.43 × 10<sup>9</sup>/L) was significantly associated with longer OS (p=0.006).
A low SII ( < 694.9) was also significantly associated with longer OS (p=0.044).
Multivariate analysis confirmed that age < 65 years and low SIRI were independent predictors of longer OS.

Conclusions

SIRI and SII are simple, cost-effective biomarkers that can predict OS in PCNSL patients.
Pre-treatment systemic immune-inflammatory status, as indicated by SIRI and SII, is associated with outcomes in PCNSL.
These findings support the use of SIRI and SII in risk stratification for PCNSL.

Keywords:

Blood cell count Malignant lymphoma Systemic immune-inflammation index Systemic inflammation response index